All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec005}
============

Drug induced liver injury (DILI) is defined as hepatotoxicity caused by various medications, herbs, or other xenobiotics, subsequently leading to abnormalities in liver tests or liver dysfunction with the reasonable exclusion of other etiologies \[[@pone.0231398.ref001]\]. Specific laboratory criteria are utilized to identify DILI: generally, a 3--5 times elevation of liver enzymes, namely transaminases (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]), alkaline phosphatase (ALP), or bilirubin, above their upper limit of normal (ULN) is required \[[@pone.0231398.ref002]\]. Altogether, in excess of a thousand medicines and chemicals have been implicated in drug induced liver injury \[[@pone.0231398.ref003], [@pone.0231398.ref004]\].

In the United States, DILI accounts for nearly 10% of the total cases of acute hepatitis, 5% of all hospital admissions, and 50% of all cases of acute liver failures \[[@pone.0231398.ref005]\]. DILI carries a mortality rate of approximately 10% \[[@pone.0231398.ref003]--[@pone.0231398.ref005]\]. It is the premier reason for drug withdrawal by the Food and Drug Administration (FDA) in the United States \[[@pone.0231398.ref005], [@pone.0231398.ref006]\].

The wide spectrum of clinical symptomatology, non-availability of specific diagnostic markers and lack of standardization between studies performed to date make it difficult to establish causality to a particular drug. Causal association to a specific drug is not a straightforward matter, as it heavilydepends on exclusion of other causes (notably viral and autoimmune hepatitis) and temporal relationship of the drug to the derangement in patient's liver function tests (LFTs) \[[@pone.0231398.ref007]\]. As a result, sometimes certain scoring systems such as Roussel Uclaf Causality Assessment Method (RUCAM) \[[@pone.0231398.ref008]\], are used to assess the probability of association. The RUCAM system is a means of assigning points for clinical, biochemical, serologic and radiologic features of liver injury which gives an overall assessment score which reflects the likelihood that the hepatic injury is due to a specific medication \[[@pone.0231398.ref009]\].

Annual incidence of DILI ranges from 1.3 to 19 per 100,000 in various databases, depending on the country of origin, type of data and method of obtaining information \[[@pone.0231398.ref010]--[@pone.0231398.ref012]\]. The largest drug category responsible for DILI is antimicrobials, led by amoxicillin-clavulanate\[[@pone.0231398.ref013], [@pone.0231398.ref014]\]. Amongst antibiotics, ATDs are another major group associated with DILI especially in the developing world. Approximately 5.3% of all the cases in the United States DILI Network (US DILIN) were reported due to isoniazid (second only to amoxicillin-clavulanate) likewise 7% of the cases in the Spanish DILI Registry were due to isoniazid alone or in combination with other drugs \[[@pone.0231398.ref013], [@pone.0231398.ref014]\]. Other common drug groups include non-steroidal anti-inflammatory drugs (NSAIDs) \[[@pone.0231398.ref010], [@pone.0231398.ref014]\], herbal and dietary supplements (HDS) \[[@pone.0231398.ref015]\] and rarely statins \[[@pone.0231398.ref013], [@pone.0231398.ref016], [@pone.0231398.ref017]\].

A growing concern for pharmaceutical industry regarding drug development is hepatotoxicity induced by the newer molecular targeted agents (MTAs) which are increasingly being used in oncology. A third of patients treated with a protein kinase inhibitor experience liver injury, with pazopanib, sunitinib and regorafenib identified as the potentially lethal agents \[[@pone.0231398.ref018]\]. Similarly, 10% of patients treated with immune checkpoint inhibitors, such as ipilimumab, are susceptible to DILI \[[@pone.0231398.ref017]\]. Additionally, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib is associated with 18.5% frequency of hepatotoxicity. It has resulted in casualties as well \[[@pone.0231398.ref019]\].

In many countries, DILI registries have been set up which record every DILI case with a formal causality determination process, providing in-depth information about the types of drugs that cause DILI, the pattern of injury and the risk of mortality and morbidity. There are few established DILI registries in the region, and no centralized, national registry. This study aims to provide an analysis of clinical presentation and outcome of patients admitted with the discharge diagnosis of DILI from Pakistan.

Patients and methods {#sec006}
====================

Ethics clearance {#sec007}
----------------

This study was reviewed and approved by ethics review committee of Aga Khan University (ERC-AKU).

Study design {#sec008}
------------

A retrospective cross-sectional study.

Study setting and population {#sec009}
----------------------------

Patients admitted at Aga Khan University Hospital Karachi Pakistan, from January 2010 through December 2016, and discharged with a diagnosis of DILI, were recruited. The course of their hospital stay was reviewed through the medical record system.

Inclusion criteria {#sec010}
------------------

Patients with suspected diagnosis of DILI with clear documentation of the possible drug implicated were included.

Exclusion criteria {#sec011}
------------------

Patients with known or suspected acetaminophen toxicity, history of bone marrow or liver transplantation before the liver injury event, history of malignancy of liver and metastasis to liver, underlying hepatitis C virus (HCV), hepatitis B virus (HBV), or nonalcoholic fatty liver disease were all excluded alongside cases with other types of underlying chronic liver disease.

Criteria for diagnosis of DILI {#sec012}
------------------------------

The diagnosis of DILI and the causal relationship between liver injury event and implicated drugs were evaluated in a formal and standardized fashion by using a causality instrument: Roussel Uclaf Causality Assessment Method (RUCAM) \[[@pone.0231398.ref009]\]. Points were awarded for seven components comprising of the following: time to onset of the injury following start of the drug, subsequent course of the injury after stopping the drug, specific risk factors (age, alcohol use, pregnancy), use of other medications with a potential for liver injury, exclusion of other causes of liver disease, known potential for hepatotoxicity of the implicated drug and response to re-challenge. The RUCAM provides a semi-quantitative evaluation of causality by assigning −3 to +3 points to each of the aforementioned seven components. Based on the final score, a causal relationship between the implicated agent and the liver injury event was categorized as highly probable (\>8), probable (6--8), possible (3--5), unlikely (1 or 2), or excluded (\<0).

Criteria for assessment of clinical patterns of liver injury {#sec013}
------------------------------------------------------------

According to the Council for International Organizations of Medical Sciences (CIOMS) criteria, DILI is classified as hepatocellular, cholestatic or mixed based on its *R*-value \[[@pone.0231398.ref009]\]. The *R*-value is defined as the serum ALT/ULN divided by the serum ALP/ULN ratio; *R*-values \> 5 were classified as hepatocellular, \< 2 as cholestatic and 2--5 as mixed injury \[[@pone.0231398.ref020]\].

Criteria for severity assessment {#sec014}
--------------------------------

The severity assessment was done according to the Chinese guidelines for the diagnosis and treatment of DILI in 2015 \[[@pone.0231398.ref021]\]. The severity was scored as follows:

1.  Mild: serum enzyme elevations with total bilirubin (TBil) \< 2.5 × ULN and International Normalization Ratio (INR) \< 1.5.

2.  Moderate: serum enzyme elevations and TBil ≥ 2.5 × ULN or an INR ≥ 1.5.

3.  Severe: serum enzyme elevations and TBil ≥ 5 × ULN with or without an INR ≥ 1.5.

4.  Acute liver failure: serum enzyme elevations and TBil ≥ 10 × ULN or a daily elevation of TBil ≥ 17.1 μmol/L, an INR ≥ 2.0 and signs of hepatic or other organ failure related to DILI.

Assessment of patient morbidity and mortality {#sec015}
---------------------------------------------

In-hospital morbidity was quantified in terms of prolonged hospital stay, defined as hospital stay for more than 5 days. Predictors of mortality and morbidity were assessed by considering patients' clinical and laboratory parameters including liver synthetic functions (prothrombin time and serum albumin).

Statistical analysis {#sec016}
--------------------

The statistical analysis was conducted by using the Statistical Package for Social Science (SPSS) (Release 19.0 standard version, copyright © SPSS). A descriptive analysis was performed and results are presented as mean ± standard deviation for quantitative variables and numbers (percentages) for qualitative variables. To analyze the risk factors for poor outcome, the categorical variables were evaluated using the chi-square test while the means were compared by Student t-test. Factors predicting prolonged hospital stay were analyzed by multivariate logistic regression analysis. To establish statistical significance, p value \<0.05 was considered significant.

Compliance with ethical requirements {#sec017}
------------------------------------

The study was undertaken upon receiving approval from Ethics Review Committee (ERC). Requirement for informed consent was waived by ERC. After completion of data collection by the authors, information was made anonymous for the statistician to proceed with data analysis.

Results {#sec018}
=======

A total of 462 DILI cases were identified ([Fig 1](#pone.0231398.g001){ref-type="fig"}), out of which 264 (57.6%) patients were male with a mean age of 50.83 (range: 20--94). By using the RUCAM model for drug causality assessment, DILI was classified as definite or highly probable in 141 (31.1%), probable in 289 (62.5%) and possible in 34 (7.4%) cases.

![Flow diagram showing selection DILI cases.](pone.0231398.g001){#pone.0231398.g001}

Pattern of liver injury {#sec019}
-----------------------

Pattern of liver injury was hepatocellular in 116 (25.1%), cholestatic in 260 (56.17%) and mixed in 86 (8.72%) patients with a discharge diagnosis of DILI ([Fig 2](#pone.0231398.g002){ref-type="fig"}).

![Type of drug induce liver injury (n = 462).](pone.0231398.g002){#pone.0231398.g002}

Severity of liver injury {#sec020}
------------------------

The severity of liver injury was found to be mild in 204 (44%), moderate in 78 (16.8%), and severe in 54 (13.8%) patients, while 116 (25.1%) cases were seen to have had liver failure due to drug intake. Mortality was significantly high in patients with liver failure (p value = 0.006). [Table 1](#pone.0231398.t001){ref-type="table"}.

10.1371/journal.pone.0231398.t001

###### Severity of DILI and relationship of age and gender with mortality (n = 462).

![](pone.0231398.t001){#pone.0231398.t001g}

              Mild n = 204(44.2%)   Moderate n = 78(16.9%)   Severe n = 64(13.9%)   ACLF n = 116(25.1%)   p value
  ----------- --------------------- ------------------------ ---------------------- --------------------- ---------
  Mortality                                                                                               
  Yes         42(20.6)              20(25.6)                 16(25)                 44(38.6)              0.006
  No          162(79.4)             58(74.4)                 48(75)                 70(61.4)              
  Age                                                                                                     
  ≤35 years   46(22.5)              16(20.5)                 12(18.8)               28(24.1)              0.19
  36--45      36(17.6)              14(17.9)                 8(12.5)                20(17.2)              
  46--55      40(19.6)              10(12.8)                 12(18.8)               26(22.4)              
  55--65      40(19.6)              18(23.1)                 12(18.8)               30(25.9)              
  \>65 yrs    42(20.6)              20(25.6)                 20(31.3)               12(10.3)              
  Gender                                                                                                  
  Male        102(50)               52(66.7)                 50(78.1)               62(53.4)              \<0.001
  Female      102(50)               26(33.5)                 14(21.9)               54(46.6)              

Presenting features of patients with DILI {#sec021}
-----------------------------------------

Encephalopathy was present in 98 (21.6%) patients on the day of hospital admission while patients who presented with abdominal pain, vomiting, jaundice and pruritus were in the following order: 57.1%, 57.1%, 54.1%, and 42.3% ([Fig 3](#pone.0231398.g003){ref-type="fig"}).

![Presenting features of patients with drug induced liver injury (n = 462).](pone.0231398.g003){#pone.0231398.g003}

Furthermore, mean total bilirubin levels, ALT and AP levels were 5.37mg/dl (range: 0.20--79.1), 358.65(range: 7--8938) IU/L and 168.68(range: 32--1040) IU/L respectively.

Drug categories causing DILI {#sec022}
----------------------------

The top three causes of DILI in our study were anti-tuberculosis drugs (ATDs) followed by homeopathic or herbal medications and antiarrhythmic drugs. Patients taking ATDs in combination with different medications are listed ([Table 2](#pone.0231398.t002){ref-type="table"}).

10.1371/journal.pone.0231398.t002

###### Patients on anti-tuberculosis drugs.

![](pone.0231398.t002){#pone.0231398.t002g}

  Combination of drugs       Number of patients n = 295 (%)
  -------------------------- --------------------------------
  ATDs alone                 182(61.6)
  ATDs with NSAID            26(8.8)
  ATDs with antibiotic       83(28.1)
  ATDs with antiepileptics   4(1.3)

Other drugs implicated are displayed on [Fig 4](#pone.0231398.g004){ref-type="fig"}.

![Drug categories causing drug induced liver injury (n = 462).](pone.0231398.g004){#pone.0231398.g004}

Predictors of mortality and morbidity {#sec023}
-------------------------------------

All patients were managed as per standards of care, essentially supportive treatment was administered. A subset of patients with severe DILI received N- acetyl cysteine, and a subset of patients required ventilator support. In-hospital mortality was 122 out of 462 (26.5%) and morbidity (quantified as prolonged hospital stay more than 5 days) was observed in 214 out of 462 (35.93%) patients. None of the patients underwent a liver transplant due to non-availability of the facility at our institution and in the city during that time period.

On multivariate analysis, mortality was significantly greater in patients with encephalopathy, male gender, hepatocellular pattern of DILI, increased INR (\>1.5), acute liver failure and patients who were on ventilator support in ICU. [Table 3](#pone.0231398.t003){ref-type="table"}.

10.1371/journal.pone.0231398.t003

###### Predictors of mortality of drug induced liver injury (n = 462).

![](pone.0231398.t003){#pone.0231398.t003g}

  Patient characteristics   Death (n = 122)   Survival (n = 340)   *p* value
  ------------------------- ----------------- -------------------- -----------
  Age, in years             53.3 ± 15.1       49.8 ± 17.0          0.03
  Gender                                                           
  Male                      80(65.6)          184(54.4)            0.03
  Female                    42(34.4)          154(45.6)            
  DM                        30(24.6)          70(20.7)             0.22
  Dyslipidemia              50(41)            108(32)              0.07
  ATT                       70(57.4)          224(66.7)            0.08
  Antibiotic                8(6.6)            20(5.9)              0.80
  Antiepileptic             0                 8(2.4)               0.08
  Antifungal                10(8.2)           16(4.7)              0.15
  Atorvastatin              10(8.2)           22(6.5)              0.57
  Chemotherapy              10(8.2)           4(1.2)               \<0.001
  Herbal                    10(8.2)           32(9.5)              0.63
  Antimalarials             6(5.6)            4(1.4)               0.02
  Digoxin                   0                 12(4.3)              0.006
  Antidepressants           2(2.0)            14(5.0)              0.17
  Altered Mental Status     46(37.7)          52(15.4)             \<0.001
  Jaundice                  74(60.7)          174(51.5)            0.08
  Pruritus                  78(63.9)          184(54.4)            0.06
  Abdominal pain            120(98.4)         326(96.4)            0.26
  N acetyl cysteine         38(31.1)          54(16)               \<0.001
  Hospital stay in days     10.7 ± 10.9       6.7 ± 6.5            \<0.001
  Intubation                32(38.1)          18(7.0)              \<0.001
  TB                        6.9 ± 12.8        4.8 ± 7.0            0.09
  IB                        2.5 ± 5.7         1.08 ± 1.4           0.007
  PT                        19.4 ± 13.0       15.0 ± 7.0           \<0.001
  INR                       1.93 ± 1.3        1.45 ± 0.65          \<0.001
  AP                        202.7 ± 183.1     165.3 ± 121.2        0.03

Likewise, prolonged hospital stay (duration of \>5 days) was associated with female gender, increased ALT, AST aspartate aminotransferase levels, use of ventilator support and mixed pattern of DILI. [Table 4](#pone.0231398.t004){ref-type="table"}.

10.1371/journal.pone.0231398.t004

###### Predictors of prolonged hospital stay (\>5 days) of patients with DILI (n = 462).

![](pone.0231398.t004){#pone.0231398.t004g}

  Patient characteristics   \< 5 days (n = 248)   \>5 days (n = 214)   *p* value
  ------------------------- --------------------- -------------------- -----------
  Age, in years             50.2 ± 16.8           51.3 ± 16.4          0.45
  Gender                                                               
  Male                      154(62.1)             112(52.6)            0.03
  Female                    94(37.9)              101(47.4)            
  DM                        48(19.4)              31(14.6)             0.17
  Dyslipidemia              51(20.6)              50(23.5)             0.45
  ATT                       43(76.8)              37(58.7)             0.03
  Antibiotics               4(7.0)                4(6.3)               0.88
  Antiepileptics            2(3.5)                1(1.6)               0.50
  Antifungal                1(1.8)                3(4.8)               0.35
  Amiodarone                5(8.8)                5(7.9)               0.86
  Statins                   6(10.5)               5(7.9)               0.62
  Chemotherapy              1(1.8)                3(4.8)               0.38
  Herbal                    4(7.0)                7(11.1)              0.45
  Antimalarials             0                     2(4.8)               0.49
  Mortality                 27(22.1)              34(32.7)             0.07
  N acetyl cysteine         21(17.4)              26(25)               0.16
  History of alcohol        1(1.8)                2(3.3)               0.58
  Intubation                7(12.5)               15(25)               0.08
  TB                        4.9 ± 9.2             6.0 ± 11.4           0.25
  DB                        2.6 ± 2.3             5.1 ± 8.6            0.03
  IB                        1.11 ± 1.2            2.72 ± 5.9           0.04
  GGT                       151.3 ± 138.0         129.8 ± 149.9        0.11
  SGPT                      308.6 ± 630.9         439.1 ± 1093.0       0.12
  AP                        177.0 ± 125.8         165.7 ± 135.7        0.35
  SGOT                      400.1 ± 765.9         695.8 ± 1416.5       0.17
  R ratio                   9.6 ± 23.8            11.6 ± 21.7          0.34

Discussion {#sec024}
==========

Drug induced liver injury is the most under-recognized and under-reported cause of liver injury, ultimately leading to underestimation of its burden. The present study analyzes hospitalized patients suffering from drug induced liver injury who were admitted in a tertiary care center in Pakistan, over a seven-year period. This is a large data set related to DILI from a developing country from where there is paucity of such kind of information.

One important finding from this study is that the order and frequency of drugs associated with DILI is different from the list provided in the report from the Drug Induced Liver Injury Network (DILIN) and the Spanish Registry \[[@pone.0231398.ref013], [@pone.0231398.ref014]\]. These studies showed that amoxicillin-clavulanate was the most common causative agent amongst the antimicrobials. A recently published review found 9 of the top 10 causes of DILI to be antibiotics; this is a measure of their hepatotoxic potential, as well as the common use and duration of treatment with these drugs \[[@pone.0231398.ref020], [@pone.0231398.ref022]\].

We found ATDs to be the most commonly implicated drug with approximately 64% of cases that were reviewed having received ATDs. This likely reflects the differences in the epidemiology of infectious diseases and corresponded to numbers observed by other studies from this region \[[@pone.0231398.ref023]\]. ATDs were followed by homeopathic and herbal medications with 9% of cases having received it, similar to other prior studies \[[@pone.0231398.ref024]\]. After ATDs, the category of drugs most frequently implicated in DILI was homeopathic and herbal medications, with a frequency within a range provided in prior studies from regions with a history of common consumption \[[@pone.0231398.ref024]\].

More than 20% of patients in our series had encephalopathy accounting for fulminant or acute liver failure at the time of presentation in the hospital. Conversely, the Spanish registry reported very low number of patients with fulminant hepatic failure with 11 out of 439 cases being classified as such \[[@pone.0231398.ref014], [@pone.0231398.ref025]\]. The high prevalence of encephalopathy in our study can be attributed to a delay in presentation to the hospital with very little knowledge about the drug being a cause of liver injury. Additionally, our center is one of the main tertiary care hospitals in Pakistan that receives an increasing number of complicated referrals: this may have resulted in more serious clinical presentations and contributed to greater DILI cases arising due to ATDs.

Another noteworthy observation deduced from our study is the fact that more than a quarter of hospitalized patients with DILI died while in the hospital. The mortality rate in our study appeared significantly high compared to that observed in several other studies, which ranges from 10 to 17.3% \[[@pone.0231398.ref010], [@pone.0231398.ref013], [@pone.0231398.ref026], and [@pone.0231398.ref027]\]. This difference in mortality is perhaps due to the fact that our series of DILI is for hospitalized patients which are expected to be more severely ill. Another factor for high mortality in our study could be the fact that ATDs was the leading cause of DILI as it has been observed in an Indian study that mortality in DILI patients on ATDs was significantly high compared to those not taking ATDs: 21.5% vs. 11.4% respectively (p = 0.02)\[[@pone.0231398.ref028]\]. Lack of facilities for liver transplantation could be another reason for high mortality in our series.

Very few studies have reported predictors of outcome for DILI which include hepatocellular damage, high bilirubin and female sex, as described by the US DILI network \[[@pone.0231398.ref015]\]. The Spanish registry and a Swedish study have described the hepatocellular pattern of damage as the most common form of liver injury associated with high incidence of liver transplantation or death if patient with jaundice \[[@pone.0231398.ref014], [@pone.0231398.ref027]\].

In a Chinese study, ATDs were found to be the primary etiological factor for fatal DILI. Additionally, the same study also identified that hepatic encephalopathy, ascites, jaundice, alcohol abuse and direct bilirubin levels were associated with the death of DILI patients \[[@pone.0231398.ref029]\]. Likewise in an Indian study, high-MELD score or a combination of ascites, encephalopathy, high bilirubin, prothrombin time, and leukocyte count were identified as predictors of mortality \[[@pone.0231398.ref028]\]. In our study, we also observed that mortality was significantly greater in patients with encephalopathy, male gender, hepatocellular pattern of DILI, increased INR (\>1.5) and patients on ventilator support.

Limitations of the present study include a retrospective study design and a sample population based in a single tertiary care center setting. Non-availability of transplantation facility for ultimate treatment of patients restricted us from reviewing the outcomes in such patients in detail.

Conclusion {#sec025}
==========

In the present study, ATDs was seen to be the most frequent cause of DILI in hospitalized patients. More than a quarter of patients died during hospital stay. As a result, care among physicians is required while prescribing potentially hepatotoxic agents. A close control of clinical and biochemical parameters is required while prescribing potentially hepatotoxic agents, especially ATDs in our region. Additionally, efforts at the national level should be undertaken to create greater public awareness about DILI especially while using ATDs.

Supporting information {#sec026}
======================
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Click here for additional data file.
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Reviewer \#1: Authors evaluated the clinical spectrum and predictors of mortality and morbidity of hospitalized patients with suspected DILI in a medical facility in Pakistan. The most frequent cause of DILI is ATDs in hospitalized patients in their study, which is different from other registries. Authors suggested that this was due to differences in the epidemiology of infectious diseases in their region. The manuscript is well written, but authors should provide more information as suggested below.

1\. Why did authors exclude patients with acetaminophen toxicity when acetaminophen is a known major cause of DILI?

2\. Authors state that their results are different from other drug registries that have examined the most frequent-causing DILI drugs due to differences in infectious disease epidemiology. Authors did not show any sort of correlation for DILI-causing drugs and diseases present in previously studied regions compared to their study/region. How can authors be sure that other biases are not present in their study, such as being a place that receives many "complicated referrals", as said by authors? This may also be a reason for the higher mortality rate seen by these authors in comparison to other studies.

3\. Figures are blurry and hard to read.

Reviewer \#2: Summary:

In this paper, authors analyzed drugs potentially associated with liver injury, including in-hospital mortality and morbidity. In 462 hospitalized patients they found administration of anti-tuberculous drugs to be the most frequent cause of liver injury.

Major comments:

1\. Are there any data what is happening out of hospital(s)? In other words how many patients with DILI do not reach hospital at all?

2\. Drug-drug interactions are mostly beyond adverse effects of medical treatment in general. Is there any evidence that antituberculotic drugs could have any interactions with other (implicated by authors in Figure 4) or alcohol (despite supposedly not in muslim population). The kind of antituberculotic drugs should be specified including duration of treatment.

3\. The in-hospital treatment is of importance. Potential differences between groups under study in in-hospital treatment should be described and/or at least discussed.

Minor comments:

1\. Was there any serious bleeding caused by coagulopathy?

2\. Was there any information regarding social status?

Conclusion:

Interesting data are presented regarding serious side effects of selected drugs on the liver function in country with supposedly very rare intake of alcohol (in contrast to most of European ... countries). Some points need to be addressed more precisely/data added. Please see above.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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20 Mar 2020

Following are our point by point response to academic Editors and reviewers comments.

Academic Editor:

1\. This has been addressed with changes in the revised manuscript files. been included in the naming of the files.

2\. The ethics committee waived requirement for informed consent on the grounds of this study being retrospective. Data was not made anonymous to the authors collecting data, but was anonymized for the statistician. This information has been included in the methods section of the manuscript.

3\. These concerns have been addressed with changes in the revised manuscripts (for reference, please see file "Manuscript with Track Changes" page 4 lines 79-82, page 7 lines 145-147 and page 11 lines 231-232)

4\. The list of authors has been amended so that each author is linked to an affiliation and the corresponding author has been identified with an \*.

5\. Figures 2-4 have been reconstructed to ensure details are clear.

6\.

The statement \"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript\" has been included in the cover letter.

Reviewer \#1: We appreciate the reviewer's identification of this point excluded from our study. However, the aim of this study is to emphasize DILI of idiosyncratic nature, as intrinsic DILI (such as that caused by acetaminophen in a dose-dependent and predictable manner) has been investigated and reproduced in animal models to elicit a more thorough understanding of liver injury in such cases.

Fontana R. J. (2014). Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology, 146(4), 914--928. <https://doi.org/10.1053/j.gastro.2013.12.032>

2\. It is very possible that "complicated referrals" and differences in infectious disease epidemiology both contribute to the ATDs becoming the most frequent-causing DILI drug in this study population. We have not come across any studies outlining established correlation between the frequency of DILI causing drugs and disease epidemiology of particular regions. We have amended the language in the manuscript to make note of the above points.

3\. Figures have been reconstructed and submitted.

Reviewer \#2:

1\. There is currently no way to quantify the proportion of DILI cases (suspected or definite) that do not reach the hospitals.

2\. Physicians and all healthcare professionals involved in patient care are trained and expected to take a thorough history, regardless of religious or cultural differences. However, the hospital does not have a routine screening questionnaire for alcohol use. Experientially, many Muslims hesitate admitting any alcohol use, which leaves room only for speculation.

Currently, all patients are given ATDs in the form of Myrin (which contains isoniazid, rifampicin, ethambutol, and pyrazinamide). We have included a table detailing what medications patients were taking besides ATDs, if any (table 2)and a modified figure 4 in the Results section.

3\. The patients were managed as per standard of care, essentially supportive treatment was administered. A subset of patients with severe DILI received N- acetyl cysteine. A subset of patients received ventilator support. This information has been added to the Discussion section.

Minor comments:

1\. Was there any serious bleeding caused by coagulopathy?

No

2\. Was there any information regarding social status?

No. Aga Khan University Hospital being a tertiary care hospital, caters to patients of all social strata.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Drug induced liver Injury is associated with high mortality - a study from a tertiary care hospital in Pakistan

PONE-D-19-34738R1

Dear Dr. Abid,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Chiara Lazzeri

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:
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PONE-D-19-34738R1

Drug induced liver Injury is associated with high mortality - a study from a tertiary care hospital in Pakistan

Dear Dr. Abid:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Chiara Lazzeri

Academic Editor

PLOS ONE
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